PURPOSE: To evaluate the measures of community human immunodeficiency virus (HIV) viral load (VL) and the association with HIV incidence among people who inject drugs (PWID). METHODS: Data were from 1986 to 1999 Urban Health Study conducted among PWID in the San Francisco Bay Area. Extant measures of community VL use mean VL among HIV + study participants, not accounting for the proportion of HIV- individuals. We compared the strength of the associations between HIV incidence and the traditionally measured mean community VL and a new prevalence-adjusted community VL, calculated by dividing the sum of VL among HIV + participants by the total participants irrespective of HIV status. RESULTS: Mean community VL was not correlated with HIV incidence in this sample of PWID (rs = 0.32, P = .28). However, prevalence-adjusted community VL was strongly correlated with HIV incidence (rs = 0.69, P = .009). Nested complimentary log-log linear models indicated that increases in community VL and prevalence-adjusted community VL were both associated with HIV incidence, but prevalence-adjusted community VL was a more sensitive measure (hazard ratio = 1.28, P = .038 and hazard ratio = 3.29, P < .001, respectively). CONCLUSIONS: The effect of community VL on HIV incidence may be stronger than previously reported. Future studies of community VL surveillance should consider accounting for the prevalence of HIV using a prevalence-adjusted community VL measure.
PURPOSE: To evaluate the measures of community humanimmunodeficiency virus (HIV) viral load (VL) and the association with HIV incidence among people who inject drugs (PWID). METHODS: Data were from 1986 to 1999 Urban Health Study conducted among PWID in the San Francisco Bay Area. Extant measures of community VL use mean VL among HIV + study participants, not accounting for the proportion of HIV- individuals. We compared the strength of the associations between HIV incidence and the traditionally measured mean community VL and a new prevalence-adjusted community VL, calculated by dividing the sum of VL among HIV + participants by the total participants irrespective of HIV status. RESULTS: Mean community VL was not correlated with HIV incidence in this sample of PWID (rs = 0.32, P = .28). However, prevalence-adjusted community VL was strongly correlated with HIV incidence (rs = 0.69, P = .009). Nested complimentary log-log linear models indicated that increases in community VL and prevalence-adjusted community VL were both associated with HIV incidence, but prevalence-adjusted community VL was a more sensitive measure (hazard ratio = 1.28, P = .038 and hazard ratio = 3.29, P < .001, respectively). CONCLUSIONS: The effect of community VL on HIV incidence may be stronger than previously reported. Future studies of community VL surveillance should consider accounting for the prevalence of HIV using a prevalence-adjusted community VL measure.
Authors: Anneke S de Vos; Maria Prins; Roel A Coutinho; Jannie J van der Helm; Mirjam E E Kretzschmar Journal: AIDS Date: 2014-03-27 Impact factor: 4.177
Authors: Myron S Cohen; Ying Q Chen; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Beatriz Grinsztejn; Jose H S Pilotto; Sheela V Godbole; Sanjay Mehendale; Suwat Chariyalertsak; Breno R Santos; Kenneth H Mayer; Irving F Hoffman; Susan H Eshleman; Estelle Piwowar-Manning; Lei Wang; Joseph Makhema; Lisa A Mills; Guy de Bruyn; Ian Sanne; Joseph Eron; Joel Gallant; Diane Havlir; Susan Swindells; Heather Ribaudo; Vanessa Elharrar; David Burns; Taha E Taha; Karin Nielsen-Saines; David Celentano; Max Essex; Thomas R Fleming Journal: N Engl J Med Date: 2011-07-18 Impact factor: 91.245
Authors: S Bassetti; M Battegay; H Furrer; M Rickenbach; M Flepp; L Kaiser; A Telenti; P L Vernazza; E Bernasconi; P Sudre Journal: J Acquir Immune Defic Syndr Date: 1999-06-01 Impact factor: 3.731
Authors: Julio S G Montaner; Viviane D Lima; Rolando Barrios; Benita Yip; Evan Wood; Thomas Kerr; Kate Shannon; P Richard Harrigan; Robert S Hogg; Patricia Daly; Perry Kendall Journal: Lancet Date: 2010-07-16 Impact factor: 79.321
Authors: Alex H Kral; Jennifer Lorvick; Lauren Gee; Peter Bacchetti; Bhupat Rawal; Michael Busch; Brian R Edlin Journal: Am J Epidemiol Date: 2003-05-15 Impact factor: 4.897
Authors: Alex H Kral; Mohsen Malekinejad; Jason Vaudrey; Alexis N Martinez; Jennifer Lorvick; Willi McFarland; H Fisher Raymond Journal: J Urban Health Date: 2010-09 Impact factor: 3.671
Authors: Colleen F Kelley; Eli S Rosenberg; Brandon M O'Hara; Paula M Frew; Travis Sanchez; John L Peterson; Carlos Del Rio; Patrick S Sullivan Journal: PLoS One Date: 2012-12-28 Impact factor: 3.240